Conclusions Across preclinical and translational studies, GLP-1RAs have emerged as promising candidates for NDD therapy, consistently modulating convergent mechanisms of pathology: IR, mitochondrial dysfunction, oxidative stress, proteostasis failure, synaptic loss, and neuroinflammation
What This Means for the Future of Weight Loss Medicine The COURAGE trials full 52-week data (including a weight-maintenance phase) is expected in late 2026
Clinical evidence for probiotics in weight management remains limited and inconclusive, with modest effects typically not meeting standards for regulatory health claims approval
These versions often come in vials as either a pre-mixed liquid or a lyophilized powder that requires reconstitution
GLP-1 Weight Loss Expectations: Both options exceed expectations when combined with a healthy diet and exercise
Availability is shown on the product page when applicable